These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19043513)

  • 1. Beneficial effect of pramipexole for motor function and depression in Parkinson's disease.
    Kano O; Ikeda K; Kiyozuka T; Iwamoto K; Ito H; Kawase Y; Sato R; Fujioka T; Araki Y; Baba S; Iwasaki Y
    Neuropsychiatr Dis Treat; 2008 Aug; 4(4):707-10. PubMed ID: 19043513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
    Rektorová I; Rektor I; Bares M; Dostál V; Ehler E; Fanfrdlová Z; Fiedler J; Klajblová H; Kulist'ák P; Ressner P; Svátová J; Urbánek K; Velísková J
    Eur J Neurol; 2003 Jul; 10(4):399-406. PubMed ID: 12823492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of pramipexole dose-response relationships in Parkinson's disease.
    Wang Y; Sun SG; Zhu SQ; Liu CF; Liu YM; Di Q; Shang HF; Ren Y; Xiang W; Chen SD
    Drug Des Devel Ther; 2017; 11():83-89. PubMed ID: 28096656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.
    Reichmann H; Brecht MH; Köster J; Kraus PH; Lemke MR
    CNS Drugs; 2003; 17(13):965-73. PubMed ID: 14533946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study.
    Barone P; Scarzella L; Marconi R; Antonini A; Morgante L; Bracco F; Zappia M; Musch B;
    J Neurol; 2006 May; 253(5):601-7. PubMed ID: 16607468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.
    Xiang W; Sun YQ; Teoh HC
    Drug Des Devel Ther; 2018; 12():2017-2024. PubMed ID: 30013321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study.
    Ning H; Zhou H; Ren J; Zhou G; Yang N; Wang Z; Yuan C; Tian Z; Chen J; Shen L; Zheng H; Zhao Y; Wang H; Liu W; Liu Z
    J Transl Med; 2022 Aug; 20(1):357. PubMed ID: 35962349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
    Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
    Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole-induced antecollis in patients with Parkinson's disease: Two cases and literature review.
    Iijima M; Osawa M; Uchiyama S; Kitagawa K
    eNeurologicalSci; 2015 Jun; 1():21-23. PubMed ID: 29468202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy.
    Rektorová I; Rektor I; Bares M; Dostál V; Ehler E; Fanfrdlová Z; Fiedler J; Klajblová H; Kulist'ák P; Ressner P; Svátová J; Urbánek K; Velísková J
    Eur J Neurol; 2005 Jan; 12(1):9-15. PubMed ID: 15613141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway.
    Gao H; Wang D; Wang YL; Mao JP; Jiang S; Yang XL
    Mol Biol Rep; 2021 Apr; 48(4):3079-3087. PubMed ID: 33891271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
    Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Delgado-Alvarado M; Navalpotro-Gómez I; Belloso-Iguerategui A; Marin C; Rodríguez-Oroz MC
    Psychopharmacology (Berl); 2020 Aug; 237(8):2419-2431. PubMed ID: 32440779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression and associated factors in nondemented Chinese patients with Parkinson's disease.
    Zhu J; Lu L; Pan Y; Shen B; Xu S; Hou Y; Zhang X; Zhang L
    Clin Neurol Neurosurg; 2017 Dec; 163():142-148. PubMed ID: 29102870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson's disease.
    Dong AQ; Yang YP; Jiang SM; Yao XY; Qi D; Mao CJ; Cheng XY; Wang F; Hu LF; Liu CF
    Acta Pharmacol Sin; 2023 Jan; 44(1):32-43. PubMed ID: 35896696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyskinesias and treatment with pramipexole in patients with Parkinson's disease.
    Piedad JC; Cavanna AE
    Parkinsons Dis; 2012; 2012():473769. PubMed ID: 22496989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.
    Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Oregi A; Belloso-Iguerategui A; Delgado-Alvarado M; Navalpotro-Gómez I; Marin C; Fernagut PO; Rodríguez-Oroz MC
    Neurobiol Aging; 2019 Mar; 75():126-135. PubMed ID: 30572183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease.
    Weiner WJ; Factor SA; Jankovic J; Hauser RA; Tetrud JW; Waters CH; Shulman LM; Glassman PM; Beck B; Paume D; Doyle C
    Parkinsonism Relat Disord; 2001 Apr; 7(2):115-120. PubMed ID: 11248592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
    Gencler OS; Oztekin N; Oztekin MF
    Ideggyogy Sz; 2022 Jan; 75(1-02):39-49. PubMed ID: 35112520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.
    Harada T; Ishizaki F; Horie N; Nitta Y; Yamada T; Sasaki T; Nagakane T; Yasumatsu Y; Nitta K; Katsuoka H
    Hiroshima J Med Sci; 2011 Dec; 60(4):79-82. PubMed ID: 22389951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.